文献速递膀胱癌与上尿路尿路上皮癌

非肌层浸润性膀胱癌患者即刻膀胱灌注丝裂霉素C的价值:一项2243例患者的前瞻性多中心随机研究

Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
PubMed 文献 · Eur Urol · 2017-07-10

该前瞻性多中心随机研究比较了经尿道膀胱肿瘤电切术(TURBT)后24小时内与2周后灌注丝裂霉素C(MMC)对非肌层浸润性膀胱癌(NMIBC)患者复发的影响。共2243例患者纳入意向性治疗分析,中危和高危组3年复发风险即刻灌注低于延迟灌注,低危组5年复发风险两组无显著差异,不良事件发生率两组无显著差异。结论认为即刻单次灌注可降低复发风险,与辅助灌注次数无关。

要点

  • 中危组3年复发风险即刻灌注20% vs 延迟灌注32%,差异有统计学意义。
  • 高危组3年复发风险即刻灌注28% vs 延迟灌注35%,差异有统计学意义。
  • 低危组5年复发风险即刻灌注43% vs 延迟灌注46%,差异无统计学意义。

核心结论

  • TURBT后即刻单次灌注降低NMIBC患者复发风险,与辅助灌注次数无关。

研究设计与样本

  • 1998年至2003年间,2844例NMIBC患者随机接受TURBT后即刻与延迟MMC灌注。
  • 患者分为低危、中危和高危组,总灌注次数分别为1次、9次和15次。
  • 主要终点为中危和高危组3年复发风险及低危组5年复发风险。

主要发现

  • 低危组5年复发风险即刻灌注43% vs 延迟灌注46%,p=0.11。
  • 中危组3年复发风险即刻灌注20% vs 延迟灌注32%,p=0.037。
  • 高危组3年复发风险即刻灌注28% vs 延迟灌注35%,p=0.007。
  • 全部患者复发风险即刻灌注27%(95%CI 24-30)vs 延迟灌注36%(95%CI 33-39),p<0.001,相对复发风险降低27%(HR 0.73,95%CI 0.63-0.85,p<0.001)。
  • 不良事件发生率即刻灌注25% vs 延迟灌注22%,p=0.08,差异无统计学意义。

局限性

  • 本研究中的风险分组与当前指南略有不同,这是本研究的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy of an immediate single chemotherapy instillation after transurethral resection of a bladder tumour (TURBT) in patients with non-muscle-invasive bladder cancer (NMIBC) remains a topic of debate. Evidence is even more scarce when an immediate instillation is followed by adjuvant instillations. OBJECTIVE: To compare the effect of a mitomycin C (MMC) instillation within 24h to an instillation 2 wk after TURBT in patients with NMIBC with or without adjuvant instillations. DESIGN, SETTING, AND PARTICIPANTS: Between 1998 and 2003, 2844 NMIBC patients were randomised for immediate versus delayed MMC instillation after TURBT. Patients were categorised in low-risk (LOR), intermediate-risk (IMR), and high-risk (HIR) groups. Total numbers of instillations in these groups were 1, 9, and 15, respectively. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary end point was 3-yr recurrence risk for the IMR and HIR groups and 5-yr risk for the LOR group. Secondary outcomes were time to recurrence and incidence of adverse events. Analyses were performed with the log-rank test, Cox-regression, and χ2 test in SPSS. RESULTS AND LIMITATIONS: A total of 2243 patients were eligible on an intention-to-treat basis. Recurrence risks were 43% and 46% in the LOR group (5-yr follow-up, p=0.11), 20% and 32% in the IMR group (3-yr follow-up, p=0.037), and 28% and 35% in the HIR group (3-yr follow-up, p=0.007), for an immediate and a delayed instillation, respectively. For all patients, the recurrence risk was 27% (95% confidence interval [CI], 24-30) in the immediate and 36% (95% CI, 33-39) in the delayed instillation group (p<0.001) with a 27% reduction in relative recurrence risk (hazard ratio: 0.73, 95% CI, 0.63-0.85, p<0.001). The incidence of adverse events did not differ significantly between treatment groups (immediate instillation 25%, delayed instillation 22%, p=0.08). The risk groups in our study differ slightly from the current guidelines, which is a limitation of our study. CONCLUSIONS: An immediate, single instillation after TURBT reduces the recurrence risk in NMIBC patients, independent of the number of adjuvant installations. PATIENT SUMMARY: A single instillation of chemotherapy after the resection of non-muscle-invasive bladder cancer reduces the recurrence risk, even if patients are treated with an adjuvant schedule of instillations.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Bosschieter J, Nieuwenhuijzen JA, van Ginkel T, et al. Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients. Eur Urol. 2017. PMID: 28705539. doi:10.1016/j.eururo.2017.06.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。